Biotech Values

[cfoofme]

June 26, 2007 06:00 AM Eastern Daylight Time
Health Canada Approves ADVR’s Application for Clinical IND
YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTCBB: ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today that a Clinical Trial Application for the use of AVR118 in cancer patients has been approved by the Therapeutic Products Division of Health Canada. This approval will allow the company to commence clinical trials in patients with histologically confirmed malignancies who present with clinically demonstrable anorexia or anorexia-cachexia syndrome.

“Our objective in seeking regulatory approval in Canada is to expand our clinical trial network in sites where we can accrue patients quickly and efficiently,” said Stephen M. Elliston, President and CEO of Advanced Viral Research Corp. “Large Canadian academic healthcare institutions typically enroll a higher proportion of patients into NCI-sponsored trials than their U.S. counterparts. Furthermore, the U.S. FDA recognizes Canadian centers as being fully compliant with U.S. clinical standards,” added Elliston.

Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR118 represents a new class of cytoprotective agent that targets, among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials, including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

For further information regarding Advanced Viral Research Corp., please visit our website at http://www.adviral.com.

Contacts
The Signature Agency
Gayle Challinor, 800-870-8700 or 919-878-8989
or
Advanced Viral Research Corp.
Stephen M. Elliston, 914-376-7383
Fax: [phone]